Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib

NCT02398825 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

14

Enrollment

OTHER

Sponsor class

Stopped low enrollment rate

Conditions

Chronic Myeloid Leukemia
Chronic Phase
Adults

Interventions

DRUG: Ponatinib

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto